(Q44642105)

English

Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model

scientific article published in December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model (English)

1 reference

Europe PubMed Central

4 December 2017

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

Didier Betbeder

object named as

Didier Betbeder

7

0 references

9

object named as

Wim Jiskoot

1 reference

Europe PubMed Central

4 December 2017

author name string

Niels Hagenaars

1

1 reference

Europe PubMed Central

4 December 2017

Enrico Mastrobattista

2

1 reference

Europe PubMed Central

4 December 2017

Harrie Glansbeek

3

1 reference

Europe PubMed Central

4 December 2017

Jacco Heldens

4

1 reference

Europe PubMed Central

4 December 2017

Han van den Bosch

5

1 reference

Europe PubMed Central

4 December 2017

Virgil Schijns

6

1 reference

Europe PubMed Central

4 December 2017

Herman Vromans

8

1 reference

Europe PubMed Central

4 December 2017

language of work or name

0 references

publication date

1 December 2008

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

26

1 reference

Europe PubMed Central

4 December 2017

51

1 reference

Europe PubMed Central

4 December 2017

6555-6563

1 reference

Europe PubMed Central

4 December 2017

A pandemic warning?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Immunogenicity of trivalent subunit and split influenza vaccines (1989-90 winter season) in volunteers of different groups of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Clinical experience with inactivated, virosomal influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

A Controlled Double-Blind Comparison of Reactogenicity, Immunogenicity, and Protective Efficacy of Whole-Virus and Split-Product Influenza Vaccines in Children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Systemic reactions to influenza B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Interventions for the interruption or reduction of the spread of respiratory viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Rational design of nasal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Live attenuated influenza vaccine in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Intranasal delivery of whole influenza vaccine prevents subsequent allergen-induced sensitization and airway hyper-reactivity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Comparative analysis of six European influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Effect of priming on subsequent response to inactivated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Influenza virosomes in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Epithelial M cells: gateways for mucosal infection and immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Transport of nanoparticles across the rat nasal mucosa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Fcgamma receptors: old friends and new family members

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Recognition of single-stranded RNA viruses by Toll-like receptor 7

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

TLR9 signaling in B cells determines class switch recombination to IgG2a

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Induction of secretory immunity and memory at mucosal surfaces

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

Inactivated influenza vaccine efficacy: diminished antigenicity of split-product vaccines in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of influenza virus matrix protein with ribonucleoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.057

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.09.057

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44642105&oldid=2030523113"